Researchers in France are using tiny antibody particles extracted from the family of animals, including camels and llamas, to produce a test they say can detect if patients have COVID-19 faster and more accurately than existing methods, Reuters news agency reported on Tuesday.
This prototype test, called CorDial-1, has not been approved for use, but initial trials on 300 samples showed a 90% accuracy rate compared to a Polymerase Chain Reaction (PCR) test, the most reliable commonly-used method of detecting COVID-19.
According to the team developing this prototype test, it can deliver results within 10 minutes, and can be used outside the laboratory, while PCR testing typically takes hours and needs lab conditions.
The CorDial-1 test uses antibody fragments called nanobodies, which are derived from camelids, a group that includes camels, dromedaries, llamas and alpacas, because they are more stable than antibodies from other creatures.
For the COVID-19 test, the nanobodies are grafted onto the surface of an electrode. When those nanobodies come into contact with the "spike" protein of the COVID-19 virus, they interact to produce a change in the electrical current across the electrode.
When the testing apparatus, a device the size of a large USB stick, is plugged into a smartphone, the current shows up as a signal on a graph.
Sabine Szunerits, of the University of Lille, who is working on the project with scientists at the University of Marseille and the French National Centre for Scientific Research, said: "Depending on the height of the signal, you can say if you are COVID positive or negative."
The next phase of the project is to run a three-month trial on more than 1,000 people, Reuters added.
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Antin to acquire clinical trial equipment provider Emsere
Hyphens Pharma licenses Cerapro skin cream to Louis Widmer for six European markets
Profusa signs French distributor to expand Lumee Oxygen rollout in Europe
Sensiva Health names new chief operating officer
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system